These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23471831)

  • 1. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist.
    Fabio KM; Guillon CD; Lu SF; Heindel ND; Brownstein MJ; Lacey CJ; Garippa C; Simon NG
    J Pharm Sci; 2013 Jun; 102(6):2033-2043. PubMed ID: 23471831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.
    Fabio K; Guillon C; Lacey CJ; Lu SF; Heindel ND; Ferris CF; Placzek M; Jones G; Brownstein MJ; Simon NG
    Bioorg Med Chem; 2012 Feb; 20(3):1337-45. PubMed ID: 22249122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
    Brownstein MJ; Simon NG; Long JD; Yankey J; Maibach HT; Cudkowicz M; Coffey C; Conwit RA; Lungu C; Anderson KE; Hersch SM; Ecklund DJ; Damiano EM; Itzkowitz DE; Lu S; Chase MK; Shefner JM; McGarry A; Thornell B; Gladden C; Costigan M; O'Suilleabhain P; Marshall FJ; Chesire AM; Deritis P; Adams JL; Hedera P; Lowen K; Rosas HD; Hiller AL; Quinn J; Keith K; Duker AP; Gruenwald C; Molloy A; Jacob C; Factor S; Sperin E; Bega D; Brown ZR; Seeberger LC; Sung VW; Benge M; Kostyk SK; Daley AM; Perlman S; Suski V; Conlon P; Barrett MJ; Lowenhaupt S; Quigg M; Perlmutter JS; Wright BA; Most E; Schwartz GJ; Lamb J; Chuang RS; Singer C; Marder K; Moran JA; Singleton JR; Zorn M; Wall PV; Dubinsky RM; Gray C; Drazinic C
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33207828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
    Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of a clinically effective dose of THY1773, a novel V
    Inatani S; Mizuno-Yasuhira A; Kamiya M; Nishino I; Sabia HD; Endo H
    Biopharm Drug Dispos; 2021 May; 42(5):204-217. PubMed ID: 33734452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.
    Lago TR; Brownstein MJ; Page E; Beydler E; Manbeck A; Beale A; Roberts C; Balderston N; Damiano E; Pineles SL; Simon N; Ernst M; Grillon C
    Psychopharmacology (Berl); 2021 Sep; 238(9):2393-2403. PubMed ID: 33970290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
    Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG
    Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
    Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
    Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
    Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95.
    Kong H; Song JK; Yenugonda VM; Zhang L; Shuo T; Cheema AK; Kong Y; Du GH; Brown ML
    Mol Pharm; 2015 Feb; 12(2):393-402. PubMed ID: 25533629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidation of plasma protein binding, blood partitioning, permeability, CYP phenotyping and CYP inhibition studies of Withanone using validated UPLC method: An active constituent of neuroprotective herb Ashwagandha.
    Singh SK; Valicherla GR; Bikkasani AK; Cheruvu SH; Hossain Z; Taneja I; Ahmad H; Raju KSR; Sangwan NS; Singh SK; Dwivedi AK; Wahajuddin M; Gayen JR
    J Ethnopharmacol; 2021 Apr; 270():113819. PubMed ID: 33460762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine.
    Bymaster FP; Chao P; Schulze H; Tran PV; Marshall RD
    Drug Metab Lett; 2013 Mar; 7(1):23-33. PubMed ID: 23826879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
    Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azetidinones as vasopressin V1a antagonists.
    Guillon CD; Koppel GA; Brownstein MJ; Chaney MO; Ferris CF; Lu SF; Fabio KM; Miller MJ; Heindel ND; Hunden DC; Cooper RD; Kaldor SW; Skelton JJ; Dressman BA; Clay MP; Steinberg MI; Bruns RF; Simon NG
    Bioorg Med Chem; 2007 Mar; 15(5):2054-80. PubMed ID: 17234419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
    Kalgutkar AS; Choo E; Taylor TJ; Marfat A
    Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
    Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.